Suciraslimab (SM03) is a human IgG1 monoclonal antibody targeting CD22, developed for rheumatoid arthritis and other B-cell mediated disorders. Its research applications include in vitro B-cell depletion assays and in vivo models for autoimmune disease studies.
Konzentration:
7.51 mg/mL
Molekulargewicht:
146.16 kDa
Reinheit:
97.42% (May vary between batches)
CAS Nummer:
[2415439-63-1]
Target-Kategorie:
Immunology/Inflammation related
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten